{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-212064","form_type":"8-K","ticker":"REVB","cik":"0001810560","company_name":"REVELATION BIOSCIENCES, INC.","filed_at":"2026-05-07T23:59:59+00:00","discovered_at":"2026-05-14T18:02:32.963024+00:00","generated_at":"2026-05-14T21:58:48.244885+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Revelation Biosciences Q1 net loss $3.0M; cash $14.1M; FDA agrees to adaptive Phase 2/3 study","bullets":["Net loss $3.0M ($2.71/share) vs $2.1M ($25.34/share) in Q1 2025; operating cash burn $3.2M.","Cash and equivalents $14.1M at March 31, 2026, up from $10.7M at Dec 31, 2025; cash runway through Q1 2027.","FDA agreed to a single adaptive Phase 2/3 study design for Gemini in acute kidney injury patients.","Received $6.7M net proceeds from January 2026 warrant inducement.","Presented positive additional data analysis from PRIME Study at AKI & CRRT 2026 conference."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-212064","json":"https://secwatch.observer/filing/0001193125-26-212064.json","markdown":"https://secwatch.observer/filing/0001193125-26-212064.md","text":"https://secwatch.observer/filing/0001193125-26-212064.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1810560/000119312526212064/0001193125-26-212064-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1810560/000119312526212064/revb-20260507.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-14T21:58:48.244885+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"b90175f1af8540db01f6e544b28c27fa73ecc7e2","claim":"REVELATION BIOSCIENCES, INC. reported three months ended March 31, 2026 results: net income $3.0 million, or $2.71 basic and diluted net loss per share.","evidence_excerpt":"31, 2026 was $3.2 million compared to net cash used for operating activities of $2.8 million for the same period in 2025. Net loss for the three months ended March 31, 2026 was $3.0 million, or $2.71 basic and diluted net loss per share compared to net loss of $2.1 million, or $25.34 basic and diluted net loss per share for the three months ended March 31, 2025.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1810560/000119312526212064/0001193125-26-212064-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"three months ended March 31, 2026"},{"label":"Net income","value":"$3.0 million, or $2.71 basic and diluted net loss per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}